Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company's phase 2 clinical trial of TXA127, the Company's lead peptide product under development as a potential treatment for Duchenne Muscular Dystrophy-associated (DMD-associated) Cardiomyopathy.

Constant Therapeutics LLC，一家专注于开发影响替代肾素-血管紧张素系统的治疗方法的生物制药公司，今天宣布，第一名患者于2024年3月3日在该公司的TXA127二期临床试验中服用，该公司正在开发的先导肽产品，可用于治疗杜兴氏肌营养不良相关（DMD相关）心肌病。

The phase 2 trial is an open-label, multi-center trial designed to evaluate the safety and efficacy in non-ambulatory patients with DMD-associated Cardiomyopathy who are 16 years and older and who are receiving systemic glucocorticoids. Patients will receive 6 months of treatment and have the option to enter a 12-month extension study.

第二阶段试验是一项开放标签的多中心试验，旨在评估16岁及以上接受全身糖皮质激素治疗的DMD相关性心肌病非卧床患者的安全性和有效性。患者将接受6个月的治疗，并可以选择进入12个月的延长研究。

The study is being conducted in Israel at Sheba Medical Center and Hadassah Medical Center and is expected to enroll 10 patients.

这项研究正在以色列的Sheba医疗中心和Hadassah医疗中心进行，预计将招募10名患者。

'This is a significant milestone for Constant and for the DMD community,' said Rick Franklin, CEO of Constant Therapeutics. 'There are few treatments for DMD patients with cardiomyopathy, and heart failure is a leading cause of death in this disease. We are excited to initiate this carefully designed trial, and we look forward to sharing the data with the DMD community upon completion of the trial.'

Constant Therapeutics首席执行官里克·富兰克林（RickFranklin）说，这是Constant和DMD社区的一个重要里程碑患有心肌病的DMD患者几乎没有治疗方法，心力衰竭是该疾病的主要死亡原因。我们很高兴启动这项精心设计的试验，并期待在试验完成后与DMD社区共享数据。”

About Constant Therapeutics LLCConstant Therapeutics LLC is a private biopharmaceutical company focused on the development of treatments that effect the Alternative Renin-Angiotensin System. The lead compound, TXA127, is a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7) and is being developed for the treatment of stroke recovery and DMD-associated Cardiomyopathy.

关于Constant Therapeutics LLC Constant Therapeutics LLC是一家私营生物制药公司，专注于开发影响替代肾素-血管紧张素系统的治疗方法。先导化合物TXA127是天然存在的肽血管紧张素（1-7）的药物制剂，正在开发用于治疗中风恢复和DMD相关性心肌病。

About TXA127TXA127 is a pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1‐7). In addition to its specific effects in cardiac dysfunction, TXA127 has shown therapeutic activity in animal models of chronic stroke, Duchenne Muscular Dystrophy (DMD), Limb‐Girdle Muscular Dystrophy (LGMD), Congenital Muscular Dystrophy (MDC1A), Marfan Syndrome and Epidermolysis Bullosa.

关于TXA127TXA127是天然存在的人肽血管紧张素-（1-7）的药物制剂。TXA127除了对心脏功能障碍有特殊作用外，还在慢性中风，杜兴氏肌营养不良症（DMD），肢带型肌营养不良症（LGMD），先天性肌营养不良症（MDC1A），马凡氏综合征和大疱性表皮松解症的动物模型中显示出治疗活性。